- Reuters Investigates
- Impact Players
- Politisphere
- Felix TV
- Freeland File
- Tech Tonic
- Moving Pictures
- Fast Forward
- Rough Cuts
- Decoder
- Money Clip
- Investing 201
- Innovations
- Breakingviews
- The Exchange
- Take 120
Latest Shows
- M
- T
- W
- T
- F
TAKE 120: Biotech Wars - Gilead Bests Biogen (2:40)
Dec. 17 - Eaton Vance's Lew Piantedosi says Gilead has the potential to double its revenues based on its new Hepatitis C treatment and, trading at a discount to competitors, is the pick over Biogen.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
